Results 221 to 230 of about 23,640 (262)

Mepolizumab for the treatment of severe eosinophilic asthma

American Journal of Health-System Pharmacy, 2017
Published data on the pharmacology, pharmacokinetics and pharmacodynamics, and clinical efficacy and safety of the interleukin-5 antagonist mepolizumab are reviewed.Asthma of the eosinophilic phenotype is characterized by persistent eosinophilic airway inflammation promoted primarily by T-helper type 2 cytokines, the key regulator of eosinophils ...
Mara N, Poulakos, Shawna M, Cargill, Melissa F, Waineo, Allen L, Wolford   +3 more
openaire   +2 more sources

Mepolizumab for severe eosinophilic asthma

Expert Review of Respiratory Medicine, 2013
In this large (616 patients), double-blind, placebo-controlled, dose-ranging study of mepolizumab (a monoclonal antibody that blocks IL-5 binding to its receptor), patients were given placebo, 75-, 250- or 750-mg mepolizumab by intravenous infusion every 4 weeks for 1 year.
openaire   +2 more sources

Mepolizumab for severe eosinophilic asthma

Expert Review of Respiratory Medicine
Severe eosinophilic asthma is a distinct asthma phenotype that is characterized by elevated blood eosinophils, frequent exacerbations and dependence on treatment with systemic corticosteroids. The development of Mepolizumab, a monoclonal antibody that targets Interleukin 5, has significantly transformed the therapeutic approach of patients with severe ...
Maria, Kallieri, Andriana I, Papaioannou, Stelios, Loukides   +2 more
openaire   +2 more sources

Histamine, Basophils and Eosinophils in Severe Asthma

Clinical Science, 1979
1. Arterial and venous whole blood and plasma histamine concentrations and eosinophil and basophil counts were determined in five patients with acute severe asthma who had not previously received steroid therapy, in five who had been maintained on steroid therapy and in a control group of nine patients with acute non-respiratory illnesses.
T J, Charles, S J, Williams, A, Seaton, C, Bruce, W H, Taylor   +4 more
openaire   +2 more sources

“Refractory” Eosinophilic Airway Inflammation in Severe Asthma

American Journal of Respiratory and Critical Care Medicine, 2004
Abstract It has been suggested that patients with refractory eosinophilic airway inflammation represent a separate “eosinophilic” asthma phenotype associated with increased morbidity and a poor prognosis. To investigate whether persistent eosinophilia in these patients is a fixed feature or can still be modified by treatment, we ...
ten Brinke, A., Zwinderman, A. H., Sterk, P. J., Rabe, K. F., Bel, E. H.   +4 more
openaire   +2 more sources

Mepolizumab for the reduction of exacerbations in severe eosinophilic asthma

Expert Review of Respiratory Medicine, 2016
Asthma affects over 300 million people worldwide and is severe in 10% of sufferers. Severe asthma is associated with greater morbidity and mortality particularly as a consequence of frequent exacerbations. Advances in approaches to phenotype the heterogeneity of severe asthma has established the importance of eosinophilic inflammation and emerging new ...
Richard, Russell, Christopher, Brightling   +1 more
openaire   +2 more sources

Mepolizumab for eosinophilic severe asthma: recent studies

Expert Opinion on Biological Therapy, 2015
In September 2014 two large clinical studies of the anti-IL-5 monoclonal antibody mepolizumab in severe asthma were published in the New England Journal of Medicine (MENSA and SIRIUS).Eosinophilic inflammation has long been recognised as a feature of asthma.
Douglas S, Robinson, Harsha H, Kariyawasam   +1 more
openaire   +2 more sources

Depemokimab (Exdensur) for Severe Eosinophilic Asthma

The Medical Letter on Drugs and Therapeutics
The FDA has approved depemokimab (Exdensur – GSK), a long-acting interleukin-5 (IL-5) antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic phenotype in patients ≥12 years old. Depemokimab is the fourth IL-5-directed treatment to be approved in the US for this indication; the IL-5 antagonists mepolizumab (Nucala)
openaire   +2 more sources

Reslizumab in the Treatment of Severe Eosinophilic Asthma: an Update

Immunotherapy, 2018
A marked heterogeneity is exhibited by asthma both clinically and at the molecular level with different phenotypes driven by diverse mechanistic pathways that require specifically targeted treatments. Biologics aimed at IL-4/13, IL-5 or IgE are proven or potentially effective treatments for patients with difficult to treat eosinophilic asthma ...
openaire   +2 more sources

Biological treatment is approved for severe eosinophilic asthma

BMJ, 2016
Draft guidance from the National Institute for Health and Care Excellence (NICE) recommends the monoclonal antibody mepolizumab as an option to treat adult patients with severe refractory asthma and raised eosinophil levels.1 The decision follows an agreement by the manufacturer, GlaxoSmithKline (GSK), to reduce the price of the drug—which has a list ...
openaire   +2 more sources